Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
5 Articles
5 Articles
Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
Inovio Pharmaceuticals (NASDAQ:INO) is preparing to launch its first approved product, VOCERYQ, after the U.S. Food and Drug Administration granted accelerated approval for the treatment of adults with recurrent respiratory papillomatosis, or RRP. President and CEO Jacqueline Shea said the company
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis - PressReach
VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026 Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe PLYMOUTH MEETING, Pa., Nov. 18, 2026 /PRNewswire/ — INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and … Continue reading "INOVIO Submits Conditi…
Inovio's Voceryq Gets FDA Approval for Rare Airway Disease
A Plymouth Meeting biotech company that spent 43 years without a single approved drug finally has one. The Food and Drug Administration cleared Inovio's injectable DNA immunotherapy Voceryq for adults with recurrent respiratory papillomatosis, a rare disease that causes recurring, usually noncancerous growths in the respiratory tract, including around the vocal cords, and can affect patients' voice and breathing. The condition is caused primaril…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium







